A randomized, double-blind, parallel-group, pharmacokinetic study of oral SCIO-469 (90 mg qd and 30 mg Tid) in female subjects with active rheumatoid arthritis.
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2010
At a glance
- Drugs Methotrexate; Methotrexate; Talmapimod
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Scios
- 22 Oct 2007 Status changed from in progress to completed.
- 03 Sep 2007 New trial record.